MARKET

ALNY

ALNY

Alnylam Pharmaceuticals Inc
NASDAQ
318.85
-9.88
-3.01%
After Hours: 318.90 +0.05 +0.02% 18:32 04/02 EDT
OPEN
323.03
PREV CLOSE
328.73
HIGH
325.49
LOW
315.90
VOLUME
872.49K
TURNOVER
--
52 WEEK HIGH
495.55
52 WEEK LOW
205.87
MARKET CAP
42.29B
P/E (TTM)
136.87
1D
5D
1M
3M
1Y
5Y
1D
A Look At Alnylam Pharmaceuticals (ALNY) Valuation After New Cardiovascular Data And Partnerships At ACC.26
Simply Wall St · 1d ago
Trump may impose tariffs on drugmakers who haven't signed MFN deals - reports
Seeking Alpha · 2d ago
Alnylam Pharma (ALNY) Gets a Buy from Barclays
TipRanks · 3d ago
Alnylam Data Update Highlights RNAi Potential And Undervalued Share Price
Simply Wall St · 3d ago
Genmab names Margarida Duarte general manager for Europe and emerging markets
Reuters · 3d ago
Alnylam’s DemonsTTRate Study: Real-World Data Could Shift the ATTR-CM Investment Story
TipRanks · 4d ago
Piper Sandler Sticks to Their Buy Rating for Alnylam Pharma (ALNY)
TipRanks · 4d ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 4d ago
More
About ALNY
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.

Webull offers Alnylam Pharmaceuticals, Inc. stock information, including NASDAQ: ALNY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALNY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALNY stock methods without spending real money on the virtual paper trading platform.